Skip to main content
Top
Published in: Malaria Journal 1/2015

Open Access 01-12-2015 | Case study

Targeting vivax malaria in the Asia Pacific: The Asia Pacific Malaria Elimination Network Vivax Working Group

Author: The Vivax Working Group

Published in: Malaria Journal | Issue 1/2015

Login to get access

Abstract

The Asia Pacific Malaria Elimination Network (APMEN) is a collaboration of 18 country partners committed to eliminating malaria from within their borders. Over the past 5 years, APMEN has helped to build the knowledge, tools and in-country technical expertise required to attain this goal. At its inaugural meeting in Brisbane in 2009, Plasmodium vivax infections were identified across the region as a common threat to this ambitious programme; the APMEN Vivax Working Group was established to tackle specifically this issue. The Working Group developed a four-stage strategy to identify knowledge gaps, build regional consensus on shared priorities, generate evidence and change practice to optimize malaria elimination activities. This case study describes the issues faced and the solutions found in developing this robust strategic partnership between national programmes and research partners within the Working Group. The success of the approach adopted by the group may facilitate similar applications in other regions seeking to deploy evidence-based policy and practice.
Appendix
Available only for authorised users
Literature
4.
go back to reference White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, et al. Averting a malaria disaster. Lancet. 1999;353:1965–7.CrossRefPubMed White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, et al. Averting a malaria disaster. Lancet. 1999;353:1965–7.CrossRefPubMed
6.
go back to reference Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Warikar N, Seal A, et al. Adverse pregnancy outcomes in an area where multidrug-resistant Plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis. 2008;46:1374–81.PubMedCentralCrossRefPubMed Poespoprodjo JR, Fobia W, Kenangalem E, Lampah DA, Warikar N, Seal A, et al. Adverse pregnancy outcomes in an area where multidrug-resistant Plasmodium vivax and Plasmodium falciparum infections are endemic. Clin Infect Dis. 2008;46:1374–81.PubMedCentralCrossRefPubMed
9.
go back to reference WHO. World Malaria Report. World Health Organization. Geneva. 2014;2014:113. WHO. World Malaria Report. World Health Organization. Geneva. 2014;2014:113.
17.
go back to reference von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J, et al. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. Malar J. 2013;12:112. doi:10.1186/1475-2875-12-112.CrossRef von Seidlein L, Auburn S, Espino F, Shanks D, Cheng Q, McCarthy J, et al. Review of key knowledge gaps in glucose-6-phosphate dehydrogenase deficiency detection with regard to the safe clinical deployment of 8-aminoquinoline treatment regimens: a workshop report. Malar J. 2013;12:112. doi:10.​1186/​1475-2875-12-112.CrossRef
20.
go back to reference APMEN. Evaluation Report: a mixed method approach using internal and external evaluation 2009–2013. Brisbane, Australia: Asia Pacific Malaria Elimination Network. 2014. APMEN. Evaluation Report: a mixed method approach using internal and external evaluation 2009–2013. Brisbane, Australia: Asia Pacific Malaria Elimination Network. 2014.
21.
go back to reference RBM. The Asia Pacific Malaria Elimination Network (APMEN) supporting the common goal of a malaria-free Asia Pacific. Progress & impact series, 11. Geneva, Switzerland: Roll Back Malaria Partnership Secretariat, 2014. RBM. The Asia Pacific Malaria Elimination Network (APMEN) supporting the common goal of a malaria-free Asia Pacific. Progress & impact series, 11. Geneva, Switzerland: Roll Back Malaria Partnership Secretariat, 2014.
23.
go back to reference APMEN. Targeting vivax malaria in the Asia Pacific 2009–2014. Brisbane, Australia: Asia Pacific Malaria Elimination Network. 2014. APMEN. Targeting vivax malaria in the Asia Pacific 2009–2014. Brisbane, Australia: Asia Pacific Malaria Elimination Network. 2014.
27.
28.
go back to reference WHO. Malaria: draft global technical strategy: post 2015. World Health Organization, Geneva, 2015. WHO. Malaria: draft global technical strategy: post 2015. World Health Organization, Geneva, 2015.
29.
go back to reference RBM. Action and investment to defeat malaria 2016–2030: for a malaria free world. Geneva: World Health Organization; 2015. RBM. Action and investment to defeat malaria 2016–2030: for a malaria free world. Geneva: World Health Organization; 2015.
30.
go back to reference WHO. Control and elimination of Plasmodium vivax malaria: a technical brief. Geneva: World Health Organization; 2015. WHO. Control and elimination of Plasmodium vivax malaria: a technical brief. Geneva: World Health Organization; 2015.
34.
go back to reference Anderson TJ, Haubold B, Williams JT, Estrada-Franco JG, Richardson L, Mollinedo R, et al. Microsatellite markers reveal a spectrum of population structures in the malaria parasite Plasmodium falciparum. Mol Biol Evol. 2000;17:1467–82.CrossRefPubMed Anderson TJ, Haubold B, Williams JT, Estrada-Franco JG, Richardson L, Mollinedo R, et al. Microsatellite markers reveal a spectrum of population structures in the malaria parasite Plasmodium falciparum. Mol Biol Evol. 2000;17:1467–82.CrossRefPubMed
36.
37.
51.
go back to reference Abba K, Kirkham AJ, Olliaro PL, Deeks JJ, Donegan S, Garner P, et al. Rapid diagnostic tests for diagnosing uncomplicated non-falciparum or Plasmodium vivax malaria in endemic countries. Cochrane Database Syst Rev. 2014;12:CD011431. doi:10.1002/14651858.CD011431.PubMed Abba K, Kirkham AJ, Olliaro PL, Deeks JJ, Donegan S, Garner P, et al. Rapid diagnostic tests for diagnosing uncomplicated non-falciparum or Plasmodium vivax malaria in endemic countries. Cochrane Database Syst Rev. 2014;12:CD011431. doi:10.​1002/​14651858.​CD011431.PubMed
56.
go back to reference Beutler E, Blume KG, Kaplan JC, Lohr GW, Ramot B, Valentine WN. International Committee for Standardization in Haematology: recommended screening test for glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Br J Haematol. 1979;43:465–7.CrossRefPubMed Beutler E, Blume KG, Kaplan JC, Lohr GW, Ramot B, Valentine WN. International Committee for Standardization in Haematology: recommended screening test for glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. Br J Haematol. 1979;43:465–7.CrossRefPubMed
58.
go back to reference Bancone G, Chu CS, Chowwiwat N, Somsakchaicharoen R, Wilaisrisak P, Charunwatthana P, et al. Suitability of capillary blood for quantitative assessment of G6PD activity and performances of G6PD point-of-care tests. Am J Trop Med Hyg. 2015;. doi:10.4269/ajtmh.14-0696. Bancone G, Chu CS, Chowwiwat N, Somsakchaicharoen R, Wilaisrisak P, Charunwatthana P, et al. Suitability of capillary blood for quantitative assessment of G6PD activity and performances of G6PD point-of-care tests. Am J Trop Med Hyg. 2015;. doi:10.​4269/​ajtmh.​14-0696.
60.
go back to reference WHO. Point-of Care G6PD testing to suport safe use of primaquine for the treatment of vivax malaria. WHO Evidence Review Group meeting report. Geneva: World Health Organization; 2014. WHO. Point-of Care G6PD testing to suport safe use of primaquine for the treatment of vivax malaria. WHO Evidence Review Group meeting report. Geneva: World Health Organization; 2014.
62.
go back to reference Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis. 2009;22:430–5.CrossRefPubMed Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis. 2009;22:430–5.CrossRefPubMed
64.
go back to reference Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. J Infect Dis. 2007;195:934–41. doi:10.1086/512242.CrossRefPubMed Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. J Infect Dis. 2007;195:934–41. doi:10.​1086/​512242.CrossRefPubMed
65.
go back to reference Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, Nandy A, et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis. 2007;195:927–33.CrossRefPubMed Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim JR, Nandy A, et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis. 2007;195:927–33.CrossRefPubMed
66.
go back to reference Craig AA, Kain KC. Molecular analysis of strains of Plasmodium vivax from paired primary and relapse infections. J Infect Dis. 1996;174:373–9.CrossRefPubMed Craig AA, Kain KC. Molecular analysis of strains of Plasmodium vivax from paired primary and relapse infections. J Infect Dis. 1996;174:373–9.CrossRefPubMed
67.
go back to reference Shretta R, Omumbo J, Rapuoda B, Snow RW. Using evidence to change antimalarial drug policy in Kenya. Trop Med Int Health. 2000;5:755–64.CrossRefPubMed Shretta R, Omumbo J, Rapuoda B, Snow RW. Using evidence to change antimalarial drug policy in Kenya. Trop Med Int Health. 2000;5:755–64.CrossRefPubMed
Metadata
Title
Targeting vivax malaria in the Asia Pacific: The Asia Pacific Malaria Elimination Network Vivax Working Group
Author
The Vivax Working Group
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2015
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-015-0958-y

Other articles of this Issue 1/2015

Malaria Journal 1/2015 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.